前收市價 | 22.18 |
開市 | 22.33 |
買盤 | 21.03 x 100 |
賣出價 | 21.19 x 200 |
今日波幅 | 20.94 - 22.42 |
52 週波幅 | 11.83 - 28.80 |
成交量 | |
平均成交量 | 799,027 |
市值 | 1.032B |
Beta 值 (5 年,每月) | 1.27 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -6.02 |
業績公佈日 | 2024年5月01日 - 2024年5月06日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 39.83 |
The threat is still emerging, but it could be significant.
Data from an early-stage study shows that treatment with REGENXBIO's (RGNX) investigational Duchenne therapy RGX-202 demonstrates early evidence of strength and motor function improvement.
REGENXBIO Inc. (NASDAQ:RGNX) Q4 2023 Earnings Call Transcript February 27, 2024 REGENXBIO Inc. misses on earnings expectations. Reported EPS is $-1.43 EPS, expectations were $-1.27. REGENXBIO Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank you […]